

Sanofi  
Form 6-K  
October 25, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of October 2012

Commission File Number: 001-31368

**SANOFI**

(Translation of registrant's name into English)

Edgar Filing: Sanofi - Form 6-K

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If  Yes  marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

In October 2012, Sanofi issued the press releases attached hereto as Exhibits 99.1 to 99.5 which are incorporated herein by reference.

**Exhibit List**

Exhibit No.	Description
Exhibit 99.1	Press release dated October 25, 2012: Third Quarter 2012 Results
Exhibit 99.2	Press release dated October 18, 2012: FDA Advisory Committee Recommends KYNAMRO for Homozygous Familial Hypercholesterolemia
Exhibit 99.3	Press release dated October 12, 2012: Genzyme Presents Second Phase III Study of Once-daily Oral AUBAGIO® (teriflunomide) Confirming Significant Impact on Disability
Exhibit 99.4	Press release dated October 9, 2012: Genzyme to Present New Data from AUBAGIO and LEMTRADA Clinical Development Programs at ECTRIMS
Exhibit 99.5	Genzyme Product Sales Statement, for the Product Sales Measuring Period ended September 30, 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: October 25<sup>th</sup>, 2012

SANOFI

By /S/ John Felitti  
Name: John Felitti  
Title: Associate Vice President,  
Corporate Law, Financial & Securities Law

**Exhibit Index**

Exhibit No.	Description
Exhibit 99.1	Press release dated October 25, 2012: Third Quarter 2012 Results
Exhibit 99.2	Press release dated October 18, 2012: FDA Advisory Committee Recommends KYNAMRO for Homozygous Familial Hypercholesterolemia
Exhibit 99.3	Press release dated October 12, 2012: Genzyme Presents Second Phase III Study of Once-daily Oral AUBAGIO® (teriflunomide) Confirming Significant Impact on Disability
Exhibit 99.4	Press release dated October 9, 2012: Genzyme to Present New Data from AUBAGIO and LEMTRADA Clinical Development Programs at ECTRIMS
Exhibit 99.5	Genzyme Product Sales Statement, for the Product Sales Measuring Period ended September 30, 2012